Growth Metrics

Quest Diagnostics (DGX) Net Cash Flow (2016 - 2026)

Quest Diagnostics' Net Cash Flow history spans 18 years, with the latest figure at -$26.0 million for Q1 2026.

  • On a quarterly basis, Net Cash Flow rose 92.82% to -$26.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $203.0 million, a 172.5% increase, with the full-year FY2025 number at -$133.0 million, down 2.31% from a year prior.
  • Net Cash Flow hit -$26.0 million in Q1 2026 for Quest Diagnostics, down from -$13.0 million in the prior quarter.
  • Over the last five years, Net Cash Flow for DGX hit a ceiling of $543.0 million in Q4 2023 and a floor of -$385.0 million in Q4 2022.
  • Historically, Net Cash Flow has averaged -$27.9 million across 5 years, with a median of -$49.0 million in 2023.
  • Biggest five-year swings in Net Cash Flow: plummeted 322.22% in 2022 and later soared 2800.0% in 2024.
  • Tracing DGX's Net Cash Flow over 5 years: stood at -$385.0 million in 2022, then soared by 241.04% to $543.0 million in 2023, then crashed by 138.31% to -$208.0 million in 2024, then surged by 93.75% to -$13.0 million in 2025, then plummeted by 100.0% to -$26.0 million in 2026.
  • Business Quant data shows Net Cash Flow for DGX at -$26.0 million in Q1 2026, -$13.0 million in Q4 2025, and $115.0 million in Q3 2025.